Liver Biology and Pathobiology
Monocrotaline promotes transplanted cell engraftment and advances liver repopulation in rats via liver conditioning†
Article first published online: 28 NOV 2006
Copyright © 2006 American Association for the Study of Liver Diseases
Volume 44, Issue 6, pages 1411–1420, December 2006
How to Cite
Joseph, B., Kumaran, V., Berishvili, E., Bhargava, K. K., Palestro, C. J. and Gupta, S. (2006), Monocrotaline promotes transplanted cell engraftment and advances liver repopulation in rats via liver conditioning. Hepatology, 44: 1411–1420. doi: 10.1002/hep.21416
Potential conflict of interest: Nothing to report.
- Issue published online: 28 NOV 2006
- Article first published online: 28 NOV 2006
- Manuscript Accepted: 22 AUG 2006
- Manuscript Received: 10 FEB 2006
- National Institutes of Health. Grant Numbers: R01 DK46952, P30 DK41296
Disruption of the hepatic endothelial barrier or Kupffer cell function facilitates transplanted cell engraftment in the liver. To determine whether these mechanisms could be activated simultaneously, we studied the effects of monocrotaline, a pyrollizidine alkaloid, with reported toxicity in liver sinusoidal endothelial cells and Kupffer cells. The effects of monocrotaline in Fischer 344 rats were examined by tissue morphology, serum hyaluronic acid levels, and liver tests (endothelial and hepatocyte injury) or incorporation of carbon and 99mTc-sulfur colloid (Kupffer cell damage). To study changes in cell engraftment and liver repopulation, Fischer 344 rat hepatocytes were transplanted into syngeneic dipeptidyl peptidase IV–deficient rats followed by histological assays. We observed extensive endothelial injury without Kupffer cell or hepatocyte damage in monocrotaline-treated rats. Monocrotaline enhanced transplanted cell engraftment without changes in transplanted cell numbers or induction of proliferation in native hepatocytes over 3 months. In monocrotaline-treated rats, transplanted cells integrated into the liver parenchyma and survived in vascular spaces. To determine whether native hepatocytes suffered inapparent damage after monocrotaline, we introduced further liver injury with carbon tetrachloride subsequent to cell transplantation. Monocrotaline sensitized the liver to carbon tetrachloride–induced necrosis, which advanced transplanted cell proliferation, leading to significant liver repopulation. During this process, we observed proliferation of bile duct cells and small epithelial cells, although transplanted hepatocytes did not appear to reconstitute bile ducts. The studies showed that perturbation of multiple liver cell compartments by monocrotaline promoted transplanted cell engraftment and proliferation. In conclusion, development of drugs with monocrotaline-like effects will help advance liver cell therapy. (HEPATOLOGY 2006;44:1411–1420.)
Many insights in mechanisms of transplanted cell engraftment and proliferation are necessary for improving results of liver-directed cell therapy. Recent studies established that cells engraft in the liver through complex mechanisms with roles in this process for hepatic sinusoidal vasomotor tone, as well as specific cell types, including liver sinusoidal endothelial cells (LSECs), Kupffer cells, and hepatic stellate cells.1–6 Consistent with these mechanisms, manipulations aimed at sinusoidal vasodilatation, disruption of the hepatic endothelial barrier, modification of the extracellular matrix receptors in LSECs, and depletion of the Kupffer cell activity significantly improved transplanted cell engraftment. This has major effects on the kinetics of liver repopulation, which can be accomplished by various types of injury in native hepatocytes for conferring selective proliferation advantages to transplanted cells.7–11
It should be appropriate to consider whether simultaneous application of modifying influences would further improve transplanted cell engraftment and proliferation. For instance, previous studies have established that the plant-derived pyrrolizidine alkaloid, monocrotaline (MCT), causes widespread endothelial toxicity in the lung, liver, and kidney.12 MCT reproduced changes associated with hepatic veno-occlusive disease in rat liver and additionally depleted Kupffer cells capable of reacting with ED2 antibody,13 which recognizes the CD163 scavenger receptor antigen. This is noteworthy because gadolinium chloride also depleted ED2-positive Kupffer cells,14 and such Kupffer cell depletion promoted engraftment of transplanted cells in the liver, consistent with an inhibitory role of Kupffer cells in this process.3 In larger doses, MCT caused hepatocyte apoptosis,15 whereas in lower doses, it promoted genotoxic DNA adduct formation in hepatocytes.16 Hepatic genotoxicity after radiation and partial hepatectomy profoundly impaired the replication capacity of hepatocytes.17 Similarly, the combination of partial hepatectomy and MCT promoted transplanted cell proliferation.18 Another pyrrolizidine alkaloid, retrorsine, shares with MCT this property of inducing transplanted cell proliferation and has been useful for investigating liver repopulation mechanisms.2, 3, 6, 7 Therefore, we considered that MCT will be useful for defining the role of multiple cell compartment-specific perturbations in transplanted cell engraftment and proliferation. In this study, we addressed questions concerning the effect of MCT on LSECs, Kupffer cells, hepatocytes, and other cells in hepatocyte transplantation. We used the well-established rat hepatocyte transplantation system, in which transplanted cells are readily identified in mutant dipeptidyl peptidase IV–deficient (DPPIV−) F344 rats by morphological and molecular assays.1–7
Materials and Methods
MCT, carbon tetrachloride (CCl4), mineral oil, and chemicals or reagents were obtained from Sigma Chemical Co. (St. Louis, MO). MCT was dissolved in normal saline and injected intravenously via the spleen in single doses of 160-200 mg/kg body weight. This route of administration was chosen to ensure first-pass delivery of the substance to the liver. Control animals received only saline. CCl4 was diluted in mineral oil (1:1 v/v), and 1 mL of CCl4per kilogram was injected intramuscularly. Antibodies were against Ki67 (mouse monoclonal, 550609; BD PharMingen, San Diego, CA), OV-6 (mouse monoclonal, a kind gift from Dr. H. A. Dunsford), CK-19 (MO80 29M; Biodesign, Saco, ME), and CD45 (mouse monoclonal, 550566; BD PharMingen). Peroxidase-conjugated goat anti-mouse immunoglobulin G was obtained from Sigma Chemical Co. (Cat #3682). Diaminobenzidine color development was performed using a commercial kit (K3465; Dako Corp., Carpinteria, CA).
Rats 8–10 weeks of age weighing 120–150 g were used. Donor F344 rats were obtained from the Division of Cancer Treatment, National Cancer Institute (Bethesda, MD). The Special Animal Core of Marion Bessin Liver Research Center provided DPPIV− F344 rats. Animals were housed under 14:10–hour light/dark cycles with unrestricted access to water and pelleted chow (PMI Nutrition International, Brentwood, MO). The Animal Care and Use Committee at the Albert Einstein College of Medicine approved animal protocols according to National Research Council guidelines (Guide for the Care and Use of Laboratory Animals, United States Public Health Services, revised 1996).
Assessment of Hepatic Endothelial Injury.
Livers were perfused through the portal vein from a 60-cm height with 30–40 mL of 0.144 mol/L cacodylate buffer followed by 60 mL 1.5% glutaraldehyde in cacodylate buffer. Liver samples were further incubated in glutaraldehyde with resin embedding and orcein staining as previously described.2–4 Ultrathin sections were examined under a JOEL transmission electron microscope (Olympus, Tokyo, Japan). Endothelial integrity was graded under ×1,000 magnification in 50 consecutive sinusoids per rat (n = 3) as (1) normal sinusoids (endothelial lining intact or <25% of the sinusoid without endothelium), (2) partial endothelial damage (25%–70% of the sinusoidal endothelium lost along with morphological damage in endothelial cells), or (3) total endothelial damage (endothelial cells lost completely).
Analysis of Kupffer Cell Function.
To demonstrate phagocytosis of carbon, Pelican no. 17 India ink (Hannover, Germany) was centrifuged at 2,000g for 15 minutes and supernatant was mixed 1:5 (v/v) with normal saline containing 1% gelatin (Bio-Rad Labs, Richmond, CA), followed by intrasplenic injection of 0.1 mL (n = 3 each). After 30 minutes, animals were sacrificed and liver samples were frozen in methylbutane at −80°C for cryosections. Kupffer cells containing carbon in zone 1 (periportal) of 100 consecutive liver lobules per sample were graded as follows3, 4: grade 1, minimal carbon incorporation; grade 2, carbon incorporated to the extent observed maximally in healthy rats; or grade 3, carbon incorporated more than the maximal extent observed in healthy rats. For assessing global Kupffer cell phagocytosis, we determined 99mTc-sulfur colloid incorporation with a commercial kit (Sulfur-colloid TechneScan, CIS-USA, Bedford, MA) as previously described.3 Rats were given 100 μCi of 99mTc-sulfur colloid intrasplenically followed by gamma imaging for 30 minutes. Time-activity curves in hepatic regions of interest were then obtained.
Cell Isolation and Transplantation.
Hepatocytes were isolated by standard two-step collagenase perfusion of the liver as previously described.5 Cells were transplanted only when >80% excluded 0.2% trypan blue dye. For transplantation, 1 × 107 fresh hepatocytes were suspended in 0.5 mL serum-free RPMI 1640 medium and injected into splenic pulp over 10–15 seconds. Hemostasis was secured with a ligature around the lower pole of the spleen.
Identification of Transplanted Cells.
Multiple liver lobes were sampled and frozen in methylbutane at −80°C. Cryosections of 5 μm thickness were fixed in chloroform acetone (1:1, vol/vol) at 4°C for 10 minutes, air-dried for 30 minutes at room temperature and subjected to DPPIV histochemistry as previously described.1–6 Integration of transplanted cells in the liver parenchyma was analyzed by colocalization of bile canalicular DPPIV and ATPase activities, as described previously.19 Transplanted cell numbers were determined by morphometry using multiple sections from various liver lobes per animal (n = 4–6 each). Typically, 100 fields centered on consecutive portal areas were scored under ×100 magnification. To analyze liver repopulation, sections were stained for DPPIV and microphotographs were obtained under ×40 magnification from multiple liver lobes per rat (n = 6) using a Spot RT digital camera (Diagnostic Instrument Inc., Sterling Heights, MI). The area occupied by transplanted cells was measured with ImageJ software (National Cancer Institute, Bethesda, MD).
Characterization of Liver Cells.
Tissues were costained for DPPIV and ATPase activities to identify biliary cells expressing only ATPase. Expression of γ-glutamyltranspeptidase expression was demonstrated using previously described histochemical methods.20 Tissue immunostaining was performed to localize CK-19 (primary antibody, 1:10; secondary antibody, 1:600), Ki67 (primary antibody, 1:500; secondary antibody, 1:150), OV-6 (primary antibody, 1:50; secondary antibody, 1:600), and CD45 (primary antibody, 1:10; secondary antibody, 1:600). For negative controls, primary antibody was omitted. For Ki67 staining, positive controls were from archival frozen tissue obtained 30 hours after two-thirds partial hepatectomy in F344 rats.
Blood was collected from rats 6 hours, 1 day, and 2 days after MCT or saline treatment. Serum was separated and stored at −20°C. Hyaluronic acid content was measured with a commercial hyaluronic acid–binding protein sandwich assay (Corgenix, Inc., Westminster, CO) according to the manufacturer's instructions.21 Serum alanine aminotransferase (ALT), alkaline phosphatase, and total bilirubin were measured using an automated clinical system.
Data are expressed as the mean ± SD. Student t test and ANOVA with a Holm-Sidak test for pairwise comparisons of mean responses in different treatment groups were used for comparing data (SigmaStat 3.1; Jandel Scientific, San Rafael, CA). A P value of less than .05 was considered significant.
To identify effective MCT doses, we studied endothelial injury by electron microscopy in rats treated with 160, 180, and 200 mg/kg MCT versus saline-treated controls (n = 3 each). Subsequent studies incorporated a 200-mg/kg dose of MCT. The hepatotoxicity of MCT was studied in rats treated with saline (n = 9) or MCT (n = 12) after 6, 24, and 48 hours (n = 3 and 4, respectively) (Fig. 1A). These analyses used measures of endothelial injury, carbon incorporation in Kupffer cells, and identification of hepatocellular damage. 99mTc-sulfur colloid incorporation was assessed in additional saline- or MCT-treated rats after 24 and 48 hours, respectively (n = 3–4 each). To analyze cell engraftment, transplanted cell numbers and their location in liver parenchyma or intravascular spaces were determined in saline- or MCT-treated rats 1, 2, 4, and 7 days as well as 1 and 3 months after cell transplantation (n = 3–5 per group per time) (Fig. 1B). In addition, transplanted cell proliferation was studied after 1 or 3 months. To determine whether MCT perturbed native hepatocytes in the long term, we examined the effect of CCl4, which was administered at 10-day intervals 10 days after cell transplantation (Fig. 1C). Controls received saline alone followed by cell transplantation (n = 6 per experiment). Changes in transplanted cell numbers were analyzed 10 days after final CCl4 administration. To demonstrate synergism between MCT and CCL4-induced hepatotoxicity, we established groups of rats (n = 6 each) with saline or MCT treatment, followed 7 days later with CCl4. In these animals, we assessed serum ALT and histological grading of hepatic inflammation as previously described22 1 day after CCl4 administration. Except for studies lasting 3 months, experiments were repeated at least twice. Repeat experiments incorporated controls to permit data comparisons within each experiment, as well as across animal groups.
MCT and Liver Sinusoidal Endothelial Cell Injury.
Initial studies established that a 200-mg/kg dose of MCT was most effective at producing endothelial injury (Fig. 2A–D). For instance, within 24 hours after administration of 200 mg/kg MCT, endothelium was totally denuded (grade 3 injury) in 50% liver sinusoids compared with such injury in only 10% and 3% sinusoids after administration of 180 or 160 mg/kg MCT, respectively (P < .001, Student t test; n = 3 each). The pattern of endothelial injury was similar 48 hours after MCT administration at these doses. Serum hyaluronic acid measurements verified these findings and indicated that MCT-induced endothelial injury manifested rapidly—as early as 6 hours (Fig. 2E)—when hyaluronic acid levels were 12-fold greater than controls (367 ± 154 ng/mL vs. 31 ± 5 ng/mL; P < .001, Student t test). The serum hyaluronic acid levels were 9-fold above normal 24 and 48 hours after MCT administration (286 ± 130 ng/mL and 293 ± 114 ng/mL, respectively; P < .001, Student t test). Use of 200 mg/kg MCT did not produce mortality in rats.
MCT and Hepatocyte or Kupffer Cell Injury.
In MCT-treated rats, morphological analysis of liver showed no obvious hepatocyte injury between 6 hours and 7 days after treatment, despite administration of up to 200 mg/kg MCT. This was verified by analysis of liver tests. For instance, 24 hours after administration of 200 mg/kg MCT, when endothelial injury was already pronounced, serum ALT levels in controls and MCT-treated rats were 31 ± 2 U/L and 53 ± 24 U/L, respectively (P value not significant), and total serum bilirubin was 0.9 ± 0.7 mg/dL and 0.5 ± 0.4 mg/dL, respectively (P value not significant).
Kupffer cell activity was unimpaired in MCT-treated rats, despite previous reports indicating depletion of ED2-reactive Kupffer cells after MCT administration.13 Kupffer cells efficiently incorporated carbon in MCT-treated rats, with a higher grade of phagocytotic activity in periportal areas compared with control animals (Fig. 3A–C). Analysis of panhepatic Kupffer cell activity using 99mTc-sulphur colloid showed no differences in the hepatic accumulation of sulphur colloid in MCT-treated and control rats (Fig. 3D).
MCT Affects Engraftment of Transplanted Hepatocytes.
In MCT-treated rats, more transplanted cells were observed in intravascular spaces, as well as within the liver parenchyma at all times (Fig. 4A–B). The increase in transplanted cell numbers was apparent after 1 day and also after 2, 4, or 7 days and 1 or 3 months after cell transplantation. In control rats, 1, 2, 4, and 7 days after transplantation, the number of transplanted cells in 50 consecutive liver lobules was within a steady range, with 101 ± 26, 108 ± 23, 98 ± 28, and 90 ± 9 transplanted cells, respectively (P value not significant; n = 4–6 rats each) (Fig. 4C). The corresponding transplanted cell number 1 month after transplantation was 129 ± 10, which was 1.3 ± 0.1–fold greater than at earlier times. In MCT-treated rats 1, 2, 4, and 7 days and 1 month following cell transplantation, we observed 7 ± 0.5−, 6 ± 0.2−, 8 ± 0.8−, 8 ± 0.7−, and 8 ± 0.1–fold more transplanted cells, respectively, in the liver parenchyma compared with corresponding controls (P < .001, ANOVA with Holm-Sidak test; n = 4–6 rats). The transplanted cell number in the liver parenchyma in MCT-treated rats was 1.4 ± 0.2–fold greater after 1 month compared with the first 7 days after cell transplantation, although this was similar to that seen in control rats. In animals followed for up to 3 months after cell transplantation, transplanted cells did not show proliferation in either control or MCT-treated rats (Fig. 4A–B). The fraction of portal vein radicles containing transplanted cells increased in MCT-treated rats compared with control rats, on average by 1.7- to 2-fold during the course of 1 day to 7 days and 1 month after cell transplantation (P < .001; ANOVA with Holm-Sidak test) (Fig. 4D). Similarly, more portal vein radicles contained transplanted cells in MCT-treated rats after 3 months (Fig. 4A–B). On the other hand, compared with the steady range and even some increase in transplanted cell numbers in the liver parenchyma, the fraction of portal vein radicles containing transplanted cells declined over time in controls, as well as in MCT-treated rats (Fig. 4D), suggesting the relative inadequacy of transplanted cell survival in this intravascular location. The absence of transplanted cell proliferation in MCT-treated cell recipients suggested a lack of increased hepatocyte turnover in animals. This was verified by Ki67 expression in tissues (Fig. 4E).
Because disruption of the hepatic endothelial barrier promotes cell engraftment in the liver,2, 4 we studied the kinetics of transplanted cell engraftment. Histochemical staining for DPPIV and ATPase activities permitted identification of bile canalicular domains in transplanted and native hepatocytes, respectively, to determine whether plasma membrane structures were promptly reconstituted and transplanted cells integrated sooner in the liver in MCT-treated rats. Transplanted cells showed reconstitution of bile canaliculi more often after 1 or 2 days in MCT-treated rats (62 ± 8%) compared with control rats (28 ± 5%) (P < .001, Student t test) (Fig. 5A–C). Transplanted cells within intravascular spaces showed reconstitution of bile canaliculi without joining the bile canalicular network in the native liver (Fig. 5D), as would be expected.
Effect of MCT Pretreatment and Kinetics of Liver Repopulation.
In view of the potential for hepatic genotoxicity of MCT,16 we determined whether improved cell engraftment in MCT-treated animals could be amplified with additional liver injury. CCl4was useful for this, in line with previous studies that have established that transplanted cells in zone 1 of the liver lobule were spared from CCl4 toxicity, which was restricted to the perivenous areas due to metabolic activity of hepatocytes in this region.23 In control rats treated with three cycles of CCl4, proliferation in transplanted cells was observed to a relatively limited extent (Fig. 6A–B), and morphometric analysis showed that not more than 1.6 ± 0.6% of the liver was replaced by transplanted cells (n = 6). On the other hand, liver repopulation in recipients of 200 mg/kg MCT and CCl4increased to 48.3 ± 7.5% (P < .001, Student t test; n = 6) (Fig. 6C). In recipients of 200 mg/kg MCT before cell transplantation, liver repopulation after 14 days immediately before the second CCl4 dose, after 21 days immediately before the third CCl4 dose, and after 1 month following three CCl4 doses was 12 ± 2%, 27 ± 5%, and 48 ± 8%, respectively (P < .001, ANOVA with Holm-Sidak test; n=5–6 each). We further observed biliary proliferation in rats treated with MCT and CCl4, which was not observed in recipients of MCT alone (Fig. 6D), suggesting that the biliary compartment had not been an original target of MCT-induced genotoxicity. The proliferating bile duct compartment and additional nonparenchymal epithelial cells showed differences in the nuclear morphology and overall organization into acinar or other arrangements. Furthermore, whereas mature bile duct cells expressed ATPase intensely (Fig. 6D), ATPase expression was often limited or absent in proliferating nonparenchymal epithelial cells. Similarly, we observed CK-19 expression or OV-6 immunostaining in mature bile duct cells, but not in this population of nonparenchymal cells (Fig. 6E–F). On the other hand, some of the nonparenchymal epithelial cells expressed γ-glutamyltranspeptidase, similar to the expression of ATPase activity in some of these cells (Fig. 6G). Immunostaining for the CD45 marker showed that these cells were not blood-derived inflammatory cells (Fig. 6H).
These findings were consistent with the activation of a heterogeneous cell population during this process of MCT plus CCl4-induced injury and suggested that MCT and CCl4 induce synergistic damage in native hepatocytes. To verify this possibility, we performed additional studies in which rats were treated with MCT or saline, followed 7 days later by CCl4. In comparison with saline treatment, prior treatment with MCT resulted in greater CCl4-induced liver injury (Fig. 7).
Targeting of multiple liver cell compartments improved engraftment and proliferation of transplanted cells. Disruption of the hepatic endothelial barrier by MCT had profound effects on transplanted cell engraftment. Judging from the extensive loss of endothelial integrity, in addition to elevated levels of serum hyaluronic acid, which is cleared by LSECs through an avid receptor-dependent process,21 it is most likely that endothelial disruption was directly responsible for improved cell engraftment in rats treated with 200 mg/kg MCT. Additional CCl4-induced synergistic damage accelerated transplanted cell proliferation, leading to significant liver repopulation within 1 month, suggesting an unmasking of genotoxic damage in hepatocytes exposed to MCT and a possible combination of this mechanism with enhanced susceptibility to reactive CCl4 metabolites, perhaps with modulation of specific P450 isoforms, similar to the induction of CYP2E1 by retrorsine.20
On the other hand, we were unable to establish an effect on cell engraftment of combined endothelial and Kupffer cell injury, because MCT did not impair Kupffer cell function in our studies. MCT was previously found to alter the balance of ED1- and ED2-immunoreactive Kupffer cells, with depletion of the latter subgroup.13, 14 However, we studied phagocytic function in Kupffer cells and demonstrated that this Kupffer cell property was intact, despite MCT-induced endothelial injury. Therefore, other manipulations will be necessary to investigate the effect of combined interference with LSECs and Kupffer cells in transplanted cell engraftment and liver repopulation.
The findings shown here should be particularly helpful in developing manipulations that could be applied in the clinical situation. Although endothelial disruption using cyclophosphamide or doxorubicin improved transplanted cell engraftment in DPPIV− rats,2, 4 MCT was far more efficient in this respect. Of course, systemic toxicities of cyclophosphamide or doxorubicin make these drugs relatively less desirable, although in the cell transplant setting, use of such drugs on only a single occasion should decrease their potential for systemic toxicity. Nonetheless, superior integration of transplanted cells in the liver parenchyma in MCT-treated rats was in agreement with the quicker passage of cells through the space of Disse and into the liver plate,24 similar to cyclophosphamide-induced endothelial disruption.2 Also, delaying cell transplantation to 48 hours after MCT improved cell engraftment (not shown), in agreement with prolonged endothelial disruption following MCT. Doxorubicin was also effective in disrupting endothelial disruption for several days, thereby providing a long window for superior engraftment of transplanted cells in rats.4 Of course, greater survival of transplanted hepatocytes within portal vein radicles indicated that MCT promoted engraftment of cells in larger venous structures. However, transplanted cells located in intravascular spaces did not associate with native hepatocytes, and the biliary apparatus was not restored in these cells. Therefore, bile produced by these cells must be secreted into the blood for clearance by either native or transplanted hepatocytes in the liver parenchyma, which should be possible.
The activation of biliary cells and small nonparenchymal epithelial cells during CCl4-induced clearance of hepatocytes exposed to MCT suggests that these cells were spared from MCT toxicity. Because MCT must be converted to toxic metabolites before DNA adducts can form,16 this will be in agreement with the absence of MCT utilization in proliferating biliary or nonparenchymal epithelial cells due to the lack of relevant P450 expression (e.g., the 3A4 isoform) for metabolizing MCT.25 The emergence of such new cell populations following extensive hepatic injury has the potential to develop additional insights into stem/progenitor cell compartments in the liver (e.g., in comparison with the “small cell” population originating in the liver of retrorsine-treated rats)26 as well as the oval cell population, which arises from within the liver itself.27, 28 Initial characterization of proliferating cells in MCT and CCl4-treated rats suggested that these cells lacked markers of mature hepatocytes (e.g., DPPIV-positive bile canalicular domains) and of mature bile duct cells (e.g., CK-19), as well as of transitional cells (e.g., OV-6). However, some of the proliferating cells did express ATPase and γ-glutamyltranspeptidase, which can be expressed by both hepatocytes and bile ducts. The small hepatocyte-like progenitor cells demonstrated previously in rats treated with retrorsine and partial hepatectomy showed a different kinetics of evolution, because those cells resembled fully differentiated hepatocytes by 14 days after partial hepatectomy.26 On the other hand, cells emanating in retrorsine/partial hepatectomy–treated rats were negative for OV-6, which was similar to the proliferating cells in MCT- and CCl4-treated rats shown here, suggesting involvement of parenchymal epithelial rather than ductal cell compartments in their origin. Analysis of the potential of small hepatocyte-like cells isolated from retrorsine/partial hepatectomy–treated rats followed by transplantation studies demonstrated the capacity of these cells to produce mature hepatocytes. In the future, such studies should be helpful in characterizing the potential of small cells identified in our studies.29
Although MCT effectively synergized with CCl4 in activating liver repopulation, neither MCT nor CCl4 is a candidate for clinical use in view of their systemic toxicities, including the oncogenic potential of MCT.30 However, it is clear that in MCT-treated rats, CCl4considerably amplified further liver injury. In previous studies, MCT induced apoptosis in hepatocytes, and inflammatory cell infiltrates were not responsible for hepatic MCT toxicity,15, 31 which was verified in our studies. Proapoptotic mechanisms have certainly been effective in liver repopulation.10 Perhaps new pharmacological approaches should be developed to reproduce MCT-like effects on LSECs and/or hepatocytes without incurring systemic toxicities. It is possible to identify suitable genotoxic manipulations for inducing proliferation in transplanted cells. For instance, radiation-based genotoxicity in combination with ischemia/reperfusion–induced oxidative stress was effective for liver repopulation in DPPIV− rats, a finding that should be clinically relevant.11
In conclusion, use of the MCT/CCl4 regimen to promote transplanted cell engraftment and proliferation in animals should be useful for experimental studies. It was clear in our studies that MCT alone did not induce liver cell proliferation, as demonstrated by Ki67 expression and lack of transplanted cell proliferation, which was different from retrorsine-induced liver injury, because retrorsine was sufficient by itself for inducing liver repopulation.32 However, in these studies, liver repopulation was slower, and 2 months were needed for an average of 40% liver repopulation and 5 months for 70% liver repopulation. In contrast, the kinetics of liver repopulation elicited by the MCT/CCl4combination was comparable in our experience to that in male DPPIV− rats conditioned with retrorsine and two-thirds partial hepatectomy, where 52 ± 8% of the liver was repopulated in 4 weeks after cell transplantation.33 However, an advantage of the MCT and CCl4 regimen was that the waiting period of several weeks needed for priming rats with retrorsine or MCT followed by two-thirds partial hepatectomy could be avoided.7, 18 Therefore, the MCT/CCl4 system can be used at relatively short notice for cell transplantation studies without the imposition of additional intra-abdominal surgery and its attendant morbidity or mortality.
- 21Hyaluronic acid uptake by the isolated, perfused rat liver: an index of hepatic sinusoidal endothelial cell function. HEPATOLOGY 1992; 17: 262–272., , , .